Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia
Reason given: Inclusion is proceeding too slowly
Key facts
- Where
- Clermont-Ferrand, Grenoble, Lille, Lyon, Nancy, Paris, and Saint-Etienne, FranceSee the 7 sites
Where in France
- CHU EstaingClermont-Ferrand, FranceNo longer taking part
- Centre Hospitalier Universitaire de GrenobleGrenoble, FranceNo longer taking part
- CHRU de LilleLille, FranceNo longer taking part
- Centre Hospitalier Lyon SudLyon, FranceNo longer taking part
- Centre Hospitalier Universitaire De NancyNancy, FranceNo longer taking part
- Hôpital de la Pitié-SalpêtrièreParis, FranceNo longer taking part
- Chu de Saint EtienneSaint-Etienne, FranceNo longer taking part
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Saint Etienne
- Trial code
- NCT03439371
- Record updated
- 13 October 2026
- Original description
This study aims at evaluating the safety and the tolerance of the micro-transplantation in elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic transplantation.Read full original descriptionShow less
A Phase II, Multicenter, Open Label Study Evaluating the Efficacy and the Tolerance of Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia (MTSA)
This study aims at evaluating the safety and the tolerance of the micro-transplantation in elderly patients with acute myeloid leukemia who are ineligible to conventional allogeneic transplantation.
Inclusion: Patient affiliated to a social security regimen or beneficiary of the same; Signed written informed consent form; Patient, ≥ 60 years-old - < 75 years-old, with established diagnosis of de novo or secondary AML with intermediate-risk or adverse-risk cytogenetic profile, or with established myelodysplasic syndromes (RAEB), in pathologically confirmed complete remission following anti-leukemic induction therapy (<5% blasts); Contra-indication to conditioning regimen in conventional allogeneic transplantation.
Exclusion: Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent; Patient with established diagnosis of acute myeloid leukemia with standard-risk cytogenetic profile; Promyelocytic leukemia t(15;17); CBF-AML t(8;21) or inv(16); Normal karyotype with a favorable molecular profile: NPM1+ and FLT3-; NPM1+, FLT3- and double mutation CEBPα or chronic myeloid leukemia in blastic phase; Refusing participation.